Special Funding,Great Bay Bio Clinical Research Project Won the First Batch of 2020 Guangdong Enterprise Science and Technology Commissioner Program

Created on:2020-11-16 10:59

logo

November 16th,2020 Press Release

 

Special Funding,Great Bay Bio Clinical Research Project Won the First Batch of 2020 Guangdong Enterprise Science and Technology Commissioner Program

 

[2020/11/16, Dongguan]On Nov. 12, the rhEPO-Fc fusion protein amount research project of Guangzhou Taili Biomedical Technology Co.Ltd. won the first batch of 2020 Guangdong Enterprises Science and Technology Specialists Special Grant Program.

 

The rhEPO-Fc project is an innovative Class 1 therapeutic biological product independently developed by Great Bay Bio, and Guangzhou Boji Medical & Biotechnological Co., Ltd. provides CRO services for the Phase I clinical trial. At present, all domestic long-acting rhEPO are in the clinical stage and no product is on the market yet. rhEPO-Fc project is in the lead in the development progress and is expected to become one of the first three domestic long-acting EPOs on the market. It is planned to complete Phase I, exempt Phase II, enter directly into Phase III clinical trials, and then apply for marketing and sales, with a definite project prospect and obvious competitive advantage.

 

 

Related stories

The First Batch of Phase I Clinical Trial Subjects for GBB’s Class 1 new Drug Has Been Enrolled

The Clinical Launch Meeting of RhEPO-Fc Innovative Drug Project Was Successfully Held in Guangdong Provincial People's Hospital

 

About EPO

Erythropoietin, a glycoprotein, acts specifically on erythroid progenitor cells, 90% of which are synthesized by the kidney. It is the main hematopoietic growth factor in the body for the proliferation and differentiation of red blood cells and the maintenance of a normal number of red blood cells in the peripheral circulation.
EPO preparation is the main drug for the treatment of anemia caused by chronic renal failure or cancer chemotherapy, and has been long-acting abroad, while the domestic generation of short-acting rhEPO has almost completed import substitution. With the upgrading trend of long-acting, it is expected that the market in China will reach 4.4~5.5 billion RMB in 2026.

 

About Guangdong Enterprise Science and Technology Commissioner Program


In order to implement the important instructions given by President Xi Jinping on the 20th anniversary of the implementation of the science and technology commissioner system, carry out the "Several Measures on Scientific and Technological Innovation to Support the Resumption of Work and the Smooth Operation of the Economy" (No. 67 [2020] of the State Science and Technology Development Zone) and the "Notice of the General Office of the Ministry of Science and Technology on the Special Action of Science and Technology Personnel Service Enterprises" (No. 59 [2020] of the State Science and Technology Office),we are actively doing our best to meet the requirements of the following key work of science and technology innovation deployed by the Provincial Science and Technology Innovation Conference, including reforming and improving the province's enterprise science and technology commissioner system, exploring a new model of enterprise science and technology commissioner "oriented to the technology needs of enterprises", attracting global scientific and technological talents to serve Guangdong enterprises' innovation and development, and further developing and strengthening the province's enterprise science and technology commissioner team. To support enterprises to achieve high quality development through innovation and provide strong support for the province to accelerate the implementation of innovation-driven development strategy, the Guangdong Provincial Department of Science and Technology on organizing the 2020 Guangdong Enterprise Science and Technology Commissioner Program was officially launched.

 

About Great Bay Bio 

Headquartered in Hong Kong, Great Bay Bio Holdings Ltd (BVI) is a newly organized high-tech enterprise dedicated to developing biotechnological services and biopharmaceutical products based on AI technology. Currently, Great Bay Bio owns several subsidiaries, including Hong Kong Great Bay Biotech Co., Ltd., Dongguan Taili Biotech Co., Ltd., and Guangzhou Taili Biomedical Technology Co., Ltd. We have invested more than USD 20 million in R&D equipment and have successfully established an independent and integrated technology platform for drug development and large-scale preparation.

 

The Company has been successively recognized as a "Patent Fostering Enterprise", "Patent Pilot Enterprise", "National High-tech Enterprise", "Dongguan City New Type R&D", and "Top Ten Foreign-funded R&D Center of Guangdong Province", "Guangdong Gene Engineering and Pharmaceutical Engineering Research Center, Guangdong Doctoral Workstation. Since 2006, we have undertaken several government projects and received funding from several provincial and national governments, including the "Guangdong-Hong Kong Key Breakthrough Project in Key Areas" and the "National Major New Drug Discovery Project".

 

 

For more details, please visit:www.greatbay-bio.com

Contact for business:info@greatbay-bio.com

Contact for media and investment: public@greatbay-bio.com

 

Home    公司新闻-English    Special Funding,Great Bay Bio Clinical Research Project Won the First Batch of 2020 Guangdong Enterprise Science and Technology Commissioner Program
PV:0
Collect